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OBJECTIVES The goal of this study was to report the early and late complications experienced in atrial
septal defect (ASD) transcatheter closure.
BACKGROUND Atrial septal defect transcatheter occlusion techniques have become an alternative to surgical
procedures. A number of different devices are available for transcatheter ASD closure. The
type and rate of complications are different for different devices.
METHODS Between December 1996 and January 2001, 417 patients (mean age: 26.6  19 years)
underwent transcatheter occlusion of secundum type ASD. Complications were categorized
into major and minor. Two different devices were used: the CardioSEAL/STARFlex in 159
patients and the Amplatzer septal occluder in 258 patients.
RESULTS Thirty-four patients experienced 36 complications during the hospitalization (8.6%, 95%
confidence interval: 6.1% to 11.1%). Ten patients underwent elective surgical repair because
of device malposition (three patients) or device embolization (seven patients). Twenty-four
patients experienced 25 minor complications: unsatisfactory device position or embolization.
Devices were retrieved using a gooseneck snare and/or a basket; 11 patients experienced
arrhythmic problems. Other complications were: pericardial effusion, thrombus formation on
the left atrial disc, right iliac vein dissection, groin hematoma, hemorrhage in the retrophar-
ynx and sizing balloon rupture. Two patients had late complications: peripheral embolization
in the left leg one year after implantation of an Amplatzer device and sudden death 1.5 year
later.
CONCLUSIONS Our series of patients with ASD by transcatheter occlusion shows that the procedure is safe
and effective in the vast majority of cases. To further reduce the complications rate, the criteria
of device selection according to ASD morphology and some technical tips during implanta-
tion are discussed. (J Am Coll Cardiol 2002;39:1061–5) © 2002 by the American College
of Cardiology Foundation
The secundum type atrial septal defect (ASD) is the fourth
most common congenital heart defect with an incidence of
3.78 per 10,000 live births (1), corresponding to 5.9% of
diagnosed congenital heart disease in children (2). The
ASD can now be treated by transcatheter occlusion tech-
nique. We report the early and late complications experi-
enced in ASD transcatheter closure.
METHODS
Patients. Between December 1996 and January 2001, 417
patients (mean age: 26.6  19 years) underwent transcath-
eter occlusion of secundum type ASD (Table 1). Of 417
patients, 34 experienced complications due to the proce-
dure. Complications were categorized into major and minor
(3). Major complications included all events leading to one
of the following: 1) death; 2) life-threatening hemodynamic
decompensation requiring immediate therapy; 3) need for
surgical intervention; and 4) significant permanent anatomic
or functional lesion resulting from catheterization. Minor
complications were defined as events that were transient and
resolved with specific treatment.
Devices and implantation technique. Two different de-
vices were used: the CardioSEAL/STARFlex (CS/SF)
(from 1996) in 159 patients and the Amplatzer septal
occluder (ASO) (from 1999) in 258 patients.
The CS/SF (Nitinol Medical Technical Inc., Boston,
Massachusetts) is a second-generation double umbrella
device that was developed from the Clamshell occluder. It
consists of a metallic framework covered, in umbrella-like
fashion, by knitted polyester fabric. The device is available
in five different sizes, 17, 23, 28, 33 and 40 mm, which can
be delivered through an 11F long sheath. The CardioSEAL
has been recently modified (StarFLEX) by the addition of a
flexible self-centering mechanism, and it can be inserted on
a front loading system of a 10F.
The ASO is constructed from 0.004-in. to 0.0075-in.
nitinol wires that are tightly woven into two flat buttons
(discs) with a 4-mm connecting waist that dictates the
device diameter. The device is available from 4-mm to
38-mm. There are a total of three Dacron polyester patches
sewn securely with polyester thread into each disc and the
connecting waist to increase the thrombogenicity of the
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device. The device is delivered through a 6F up to 12F long
sheath.
The criteria for using each device in our center changed
during time; from 1996 to 1999 only the CS/SF has been
used. After 1999, when the ASO became available, we
preferred to close an ASD bigger then 18 mm only with the
new device.
In all patients, implantation was carried out under general
anesthesia. Before starting the catheterization, transesoph-
ageal echocardiographic examination was undertaken using
a multiplane probe. Standard catheterization of the right
heart was then performed through the right femoral vein,
taking recordings of pressures and blood samples to calcu-
late Qp/Qs ratio. Angiographic visualization of the defects
was achieved by injection of a contrast material in the left
atrium or the right upper pulmonary vein in the left anterior
oblique view with cranial angulation. Heparin (100 IU/kg)
and antibiotic prophylaxis were given routinely. Meditech or
Numed balloons were used to establish the stretched diam-
eter of the defect. Implantation was performed under
fluoroscopic and echocardiographic control. After position-
ing a long sheath in the left atrium, the device was attached
to its delivery wire and advanced within the sheath until the
distal disc was deployed in the left atrial cavity. Both the
sheath and delivery system were then slowly withdrawn
towards the atrial septum. The proper position of the distal
disc is confirmed on transesophageal echocardiography
(TEE), and then the proximal disc was opened on the right
side of the atrial septum by withdrawing the sheath.
Interference of the device with the caval or pulmonary veins
or with the atrioventricular valves was checked echocardio-
graphically once deployment was complete. If all findings
were satisfactory, the device was released.
Protocol for follow-up. All patients underwent clinical
examination, electrocardiography, chest radiography in two
Abbreviations and Acronyms
ASD  atrial septal defect
ASO  Amplatzer septal occluder
CS/SF  CardioSEAL/STARFlex
TEE  transesophageal echocardiography
Table 1. Patient Overview
Name
Age
(yrs) Gender
Weight
(kg)
Height
(cm)
Implantation
Date
ASD
TTE
(mm)
ASD
TEE
(mm)
ASD
Balloon
(mm) Qp:Qs
Device
Size
(mm)
Device
Type
Procedure
Time
(min)
Fluoro
Time
(min)
1 BM 8.7 M 43 137 12/1996 13 15 16 2 33 CS/SF 70 27
2 ME 14.4 F 50 170 3/1997 13 13 14 2 28/33 CS/SF 160 66
3 CC 17.8 F 56 165 7/1997 15 17 20 3 40 CS/SF 100 30
4 TF 35.4 F 63 160 7/1997 15 15 20 3.7 40 CS/SF 80 26
5 CD 8.9 M 25 150 12/1997 6 5 7 1.4 17 CS/SF 180 49
6 DPA 22.3 F 81 163 2/1998 17 16 23 2 40 CS/SF 80 30
7 BS 10.5 F 33 147 3/1998 16 14 17 3.1 33/40 CS/SF 130 48
8 MB 27 F 58 167 2/1998 14 15 17 1.8 33/40 CS/SF 85 29
9 FE 6.8 F 26 112 9/1998 12 15 20 1.6 20 ASO 57 16
10 ZO 51 M 77 175 11/1998 15 18 20 2.2 40 CS/SF 55 12
11 CA 37.2 M 73.8 185 12/1998 10 21 24 1.53 33/40–26 CS/SF 120 63
12 SA 13 M 52 155 2/1999 12 16 18 1.8 18 ASO 55 11
13 CF 34.4 F 55.5 162 2/1999 14 12 18 3.7 18 ASO 80 18
14 GA 35 F 61 165 4/1999 12 16 19 1.6 19 ASO 59 13
15 RMG 43 F 79 160 5/1999 19 22 26 2 26 ASO 100 27
16 MB 5.7 F 19.7 122 7/1999 19 20 22 4.67 22 ASO 55 22
17 ZL 56 F 68 164 2/2000 19 20 27 2 28 ASO 50 18
18 TE 15.2 F 56 170 2/2000 15 18 20 2.5 20 ASO 65 19
19 ZV 13.5 M 45 159 3/2000 19 21 24 1.8 24 ASO 70 20
20 BL 67.7 F 65 155 3/2000 15 17 24 1.5 24 ASO 50 18
21 EA 5.8 M 15 107 5/2000 11 15 19 1.5 19 ASO 75 14
22 GV 28.6 F 60 166 6/2000 20 30 30 1.6 30 ASO 60 10
23 MA 12.4 M 51 140 6/2000 19 29 30 3 30 ASO 75 16
24 MV 18.2 F 63 1.6 6/2000 11 8 15 2 28/33 CS/SF 110 62
25 FC 68 F 78 155 7/2000 18 20 1.8 22 ASO 90 16
26 FA 35 M 93 162 8/2000 16 20 26 2.2 26 ASO 120 6
27 UL 55 F 53 157 9/2000 10 13 13 13 ASO 90 18
28 MM 4.8 M 14 89 9/2000 13 15 18 1.7 18 ASO 75 10
29 EA 18 F 68 169 10/2000 20 23 28 2.5 28 ASO 84 21
30 AS 22.7 F 45 154 11/2000 18 22 24 2.6 24 ASO 60 13
31 FMT 36 F 45 1.65 12/2000 19 25 30 2.8 30 ASO 54 18
32 CA 37.2 F 71.50 170 12/2000 8 11 13 1.9 23 CS/SF 60 25
33 CD 60 F 60 160 1/2001 17 19 32 1.6 34 ASO 103 37
34 AC 29 M 78 172 1/2001 13 14 19 2.3 18 ASO 55 18
ASD atrial septal defect; ASOAmplatzer septal occluder; CS/SFCardioSEAL/STARFlex; TEE transesophageal echocardiography; TTE transthoracic echocardiography.
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projections and transthoracic echocardiography before dis-
charge. The same procedures were performed at 1, 6 and 12
months after the implantation. Aspirin, at a dose of 5 mg kg
daily, was recommended from six months after implanta-
tion.
RESULTS
The overall incidence of complications was 8.6% (95%
confidence interval: 6.1% to 11.1%) (36/417). Thirty-four
patients experienced 36 complications during the hospital-
ization: 11 major and 25 minor. This incidence includes the
learning curve for each device. The embolization/
malposition was the most common complication (3.5%),
accounting for almost half of the events (16 complications in
15 patients; 47% of all complications).
Seven patients had device embolization that needed
surgical retrieval. In four patients the device was a CS/SF
(Patients 1, 3, 4, 10); the other three patients had an ASO
implanted (Patients 19, 23, 29). Three more patients
underwent elective surgical repair because of malposition of
the device (Patients 6, 13, 16). In four patients the device
was delivered but, because of an unsatisfactory position
(Patients 2, 7, 24) or embolization (Patient 8), it was
retrieved using a gooseneck snare and/or a basket; a second
device was successfully implanted. The embolized/
malpositioned CS/SF were 40-mm in five cases, 33-mm in
four cases and 28-mm in two cases. Embolization of the
ASO occurred with devices approximately or bigger than
24-mm. Malposition occurred with 19-mm and 22-mm
devices, and, in one of those, it was related to accidental
detachment of the device inside the delivery sheath. Several
maneuvers had been performed in order to find the proper
position for the deployment of the distal disc unscrewing
the device from its delivery cable. One patient (Patient 11)
experienced both malposition (CS/SF 33-mm) and embo-
lization in the right ventricle at the second attempt (CS/SF
40-mm) 6 h after implantation. The ASD was closed with
an ASO 26-mm. One patient (Patient 24) had a malposi-
tion of his device (CS/SF 28-mm); using a gooseneck snare,
the device was pulled back into a 14F introducer up to the
common femoral vein where it was surgically retrieved. The
ASD was then closed using a CS/SF 33-mm. Arrhythmias
are the next most common complication (2.6%). Eleven
patients experienced arrhythmic problems: atrial fibrillation
requiring electrical cardioversion (Patients 13, 14, 15, 18,
23, 31), atrial fibrillation with spontaneous resolution (Pa-
tients 11, 22) and supraventricular tachycardia with spon-
taneous resolution (Patients 12, 26). In Patient 23 during
electrical cardioversion the device embolized a few minutes
after implantation; at the TEE control, no residual shunt
was detected before cardioversion. Patient 9 had a complete
atrioventricular block immediately after device implanta-
tion. The device (ASO 18-mm) was then removed with a
complete sinus rhythm recovery 3 h later. He underwent
successful closure with a 14-mm ASO one year later.
Electrical cardioversion was effective in five cases. In the
remaining patients, sinus rhythm returned spontaneously.
None of these patients experienced palpitations before the
procedure, and the electrocardiogram was normal for all of
them.
Pericardial effusion was experienced by two patients
(Patients 17 and 27). Patient 17 was treated medically and
showed complete resolution of the effusion 20 days later; the
preprocedure echocardiogram on this patient did not show
pericardial effusion. The mechanism of this complication in
that patient is not clear.
Patient 27 had a perforation due to the guidewire and
needed surgical drainage of the effusion in the cath lab. This
patient underwent complete ASD closure.
Patient 20 had a thrombus formation on the left atrial
disc immediately after delivery; she was fully heparinized.
She was treated with anticoagulant therapy for six months
with complete resolution at the TEE control (Fig. 1). There
was right iliac vein dissection (Patient 5) treated by implan-
tation of two stents, groin hematoma (Patient 25) requiring
surgical revision, hemorrhage in the retropharynx (Patient
28).
In Patient 33 the sizing balloon ruptured (MediTech
33-mm) and was retained along the long wire. The ruptured
balloon was retrieved with a basket catheter from the right
femoral vein. Two patients had late complications. Patient
30 was reported to have experienced peripheral emboliza-
tion in the left leg one year after implantation of an
Amplatzer device. She required surgical retrieval of the
distal peripheral embolus followed by anticoagulation treat-
ment for one month. Patient 34 died suddenly 1.5 years
Figure 1. Transesophageal echocardiography follow-up of a patient with thrombus in the left Amplatzer septal occluder (ASO) disc. (A) Thrombus (arrow)
in the left ASO disc immediately after device implantation. (B) Thrombus reduction (arrow) after three months anticoagulant therapy. (C) Left ASO disc
thrombus free (arrow) after six months anticoagulant therapy. LA  left atrium; RA  right atrium.
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later. No post mortem data are available, and we do not
know whether the event is related to the device implanted.
DISCUSSION
In the last 50 years cardiac catheterization has changed its
primary role from a diagnostic investigation to that of a
therapeutic procedure. Most recently, ASD transcatheter
occlusion techniques have become an alternative to surgical
procedure using cardiopulmonary bypass. A number of
different devices are available for transcatheter ASD closure,
all of them with demonstrated advantages and disadvan-
tages. The type and rate of complications are different
among different devices (4–10) (Table 2). In our experience
the embolization/malposition was the most common com-
plication. Devices usually embolize in the main pulmonary
artery (89% in our group). Once the device embolizes, two
different options are possible: 1) retrieve the device by a
gooseneck snare or a basket catheter, 2) refer the patient to
the surgeon. The last option is indicated when the size of
the device is among the largest; the surgeon will retrieve the
device and close the ASD at the same time. If we decide to
attempt the retrieval, an introducer of at least 12F to 14F
size is inserted to accommodate the device captured by a
gooseneck snare or a basket catheter. Such an attempt can
be carried out with CS/SF. An embolized/malpositioned
ASO, in our experience, is irretrievable. Among the five
cases with the CS/SF 40-mm device, at least four had a
satisfactory position after release; nevertheless, they embo-
lized within 24 h. Therefore, we became convinced that
arms are too weak to grab the septal margins and hold the
device in place with sufficient stability. The 40-mm device
was then abandoned in our practice, and the ASO device
became the first choice for closing defects larger than
18 mm. Our personal guidelines are:
1) for ASD larger than 18 mm, use ASO device;
2) where several maneuvers are needed for positioning
ASO, remember to screw the cable on the device again
to avoid accidental detachment; and
3) once the ASO has detached from its cable, it becomes
difficult to retrieve.
Arrhythmias are the next most common complication.
For patients who experienced atrial fibrillation or supraven-
tricular tachycardia after ASO device implantation, a pos-
sible explanation could be the stretching of the interatrial
septum by the central waist of the device.
Thrombus formation in the left atrial disk immediately
after the procedure was experienced in a 67-year-old patient
suffering from systemic hypertension and with evidence of
spontaneous contrast on echocardiogram. To avoid this
complication, it is now our policy to start oral antiaggrega-
tion therapy one day before the procedure in all patients.
We do not start anticoagulation therapy because we do not
have criteria to define the high-risk patients that need it.
The rupture of the sizing balloon is an unpredictable event
because it seems to be related to the balloon itself. This
complication was managed by locating the balloon outlined
by some contrast material along the long wire and by
retrieving it using a basket catheter.
The other complications (right iliac vein dissection, groin
hematoma, retropharynx hemorrhage) were related to hu-
man mismanagement during the procedure. The major
complication reported in Patient 34, that is, sudden death,
is quite worrisome and needs further investigations in other
large series. We cannot understand how a device implanted
1.5 year before could cause sudden death. It is, however, our
responsibility to report it because there are no other known
reasons to explain this event in a young man of good health
of 34 years of age. Peripheral embolization in Patient 19 was
clearly related to the presence of thrombi in the device as
detected at the TTE. A nonhypercoagulable state was
found. The patient had experienced severe gastrointestinal
tract infectious disease. This complication is very important
because it tells us that endothelization of the device is not
completed after six months, and some predisposing factors,
such as an infection, can favor thrombus formation on the
device beyond the period of antiaggregation treatment.
Table 2. Complications Reported by Different Authors
Reference Device
Total
Patients
# of Major
Complications
Device
Embolization Surgery CV PM PE Other
Walsh et al. (4) Sideris 33 1 1 0 1
ASO 39 1 1 1 0
Sievert et al. (5) ASDOS 154 11 2 11 0 5 2 infectious endocarditis, 2 thrombus
formation
Carminati et al. (6) CS 79 3 3 2 0
SF 38 1 1 1 0
Berger et al. (7) ASO 61 1 1 1 0
Chan et al. (8) ASO 100 0 0 1 transient ST elevation, 1 transient
AB block, 1 presumed deep vein
thrombosis, 1 presumed TIA
Waight et al. (9) ASO 77 3 2 0 1
Hijazi et al. (10) ASO 18 1 1 0
AB  atrioventricular block; ASO  Amplatzer septal occluder; CS  CardioSEAL; CV  electrical cardioversion; PE  pericardial effusion; PM  pacemaker; SF 
STARFlex; TIA  transient ischemic attack.
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Conclusions. Our series of patients with ASD treated with
transcatheter occlusion shows that the procedure is safe,
with a low rate of early and late complications. However,
some aspects need further and longer investigations, espe-
cially the possibility of late thrombus formation on the
device, systemic embolization and, the most worrisome
event, sudden death.
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